Georgia Medicaid now covers eXciteOSA®, expanding access to innovative daytime sleep apnea therapy and reducing healthcare ...

Anticipate topline data from pivotal Advance-HTN trial in March 2025 and pivotal Phase 3 Launch-HTN trial in mid first half of 2025 – – Completed enrollment in Explore-CKD Phase 2 trial and anticipate ...

If you have sleep apnea, you might be wondering if a smart mattress can help manage symptoms. We put that question to Dr ...

Beyond treating diabetes and helping people lose weight, GLP-1s may also improve libido. But the reasons are as complex as ...

During its fourth-quarter earnings call this week, Inspire Medical disclosed that it has become the subject of a civil probe ...

CEO Tim Herbert told investors the company received a civil investigative demand from the Department of Justice in January ...

The Department of Justice is investigating implant maker Inspire Medical Systems for its marketing, promotion and reimbursement practices, the company disclosed to investors Monday. Inspire, one of ...

When one spouse has a mental illness, the mental health of the other spouse is negatively impacted. Discover some notable ...

A new study adds to a growing body of research suggesting a potential link between popular GLP-1 medications like Ozempic and vision loss.

In my twenties, I saw my episodes as a (mostly) harmless quirk, akin to sleep walking. They didn’t always keep me in my family’s good graces, but I felt otherwise fine. I brushed them off for years.

Axsome Therapeutics, Inc. (NASDAQ:AXSM – Get Free Report) has received a consensus rating of “Buy” from the sixteen ratings firms that are covering the stock, MarketBeat.com reports. Sixteen research ...

Axsome Therapeutics (NASDAQ:AXSM – Get Free Report) had its price objective boosted by analysts at Leerink Partners from $110 ...